This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bavarian Nordic Announces Presentation Of PROSTVAC(R) At The 2013 ASCO Annual Meeting

KVISTGAARD, Denmark, May 27, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA) announced today that a new planned trial of PROSTVAC® in combination with enzalutamide will be presented as "Trials in Progress" poster at the 2013 ASCO Annual Meeting in Chicago, IL from May 31 to June 4. Additionally, an abstract evaluating the safety profile of poxviral vaccines from 9 different clinical trials of PROSTVAC® and CV-301 has been published in connection with the conference.

Visit the Bavarian Nordic booth, #5100, at ASCO to find out more about the PROSTVAC® and the PROSPECT clinical trial - a single global, randomized, double-blind, placebo-controlled Phase 3 study of PROSTVAC® in prostate cancer patients with metastatic disease who have failed hormone therapy.

Bavarian Nordic will also be hosting a PROSTVAC® update and reception on Saturday, June 1, 2013 in Chicago, Illinois. Speakers include principal investigator for the PROSPECT trial, James L. Gulley, M.D., Ph.D., Director of the Clinical Trials Group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI), Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center and James Breitmeyer, President of Bavarian Nordic's Cancer Vaccine Division. For registration and more information on this event, visit http://www.bavarian-nordic.com/asco2013 .

About Bavarian Nordic

Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and is being developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in nearly 600 patients. In infectious diseases, the company's lead program is IMVAMUNE®, a non-replicating smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE® is currently in clinical Phase 3 development and marketing authorization applications have been filed in EU and Canada. For more information, visit www.bavarian-nordic.com .

CONTACT: Anders Hedegaard, President & CEO
         Phone +45 23 20 30 64

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs